WuXi Biologics Announces GMP Release of Its First North American Biomanufacturing Facility in Cranbury, New Jersey

Rhea-AI Summary

WuXi Biologics has announced the GMP release of its first North American biomanufacturing facility, MFG18, located in Cranbury, New Jersey. The facility has an initial capacity of 4,000L, expanding to 6,000L, and utilizes single-use technology. This strategic move positions WuXi closer to its U.S. customer base amidst a growing biopharma cluster. The site employs over 150 people, expected to rise to 250. This expansion aligns with WuXi's Global Dual Sourcing Strategy, enhancing its clinical manufacturing capacity and service capabilities worldwide.

Positive

• Launch of GMP phase I drug substance manufacturing facility in Cranbury, NJ
• Initial capacity of 4,000L, expanding to 6,000L, enhancing production capabilities
• Strengthens position in U.S. biopharma market and proximity to major customers
• Supports the Global Dual Sourcing Strategy, diversifying manufacturing locations
• Job creation with 150 employees expected to grow to over 250

Negative

• None.

CRANBURY, N.J., Aug. 31, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today announced the release of its GMP phase I drug substance clinical manufacturing facility, MFG18, in Cranbury, New Jersey.   

The site's clinical manufacturing operations have an initial capacity of 4,000L and will grow to 6,000L, utilizing only single-use technology, adding to the Cranbury site's full process development capability. It is WuXi Bio's first GMP manufacturing facility in North America and was established in response to the growing need of customers worldwide. 

The 154,448 square foot New Jersey location puts WuXi Biologics closer to the majority of its customers headquartered in the U.S. and is situated within a growing biopharma cluster. The facility is a key piece of WuXi Biologics' Global Dual Sourcing Strategy, ensuring that products can be manufactured, and materials sourced at multiple WuXi Biologics locations around the world.  The site currently employs over 150 people and anticipates over 250 employees when in full operation.   

"We congratulate WuXi Biologics for selecting Cranbury, New Jersey for its first GMP biomanufacturing site in North America and on achieving GMP release for that site," said Debbie Hart, President and CEO of BioNJ, New Jersey's statewide trade association representing research-based life sciences companies and stakeholders.  "We applaud the 150 New Jersey-based employees who made it possible. This is a great milestone for both WuXi Biologics and New Jersey as it brings significant clinical manufacturing capacity to the State's booming life sciences cluster." 

Dr. Bill Aitchison, WuXi Biologics' Senior Vice President and Head of Global Manufacturing, noted, "The addition of a GMP manufacturing facility in the United States is a significant step for WuXi Biologics and a proud moment for me and our 300 US-based employees supporting our facilities in New Jersey, Pennsylvania and Massachusetts." 

Dr. Chris Chen, CEO of WuXi Biologics, remarked, "We are thrilled with the release of our first GMP biomanufacturing facility in North America.  This is a great achievement for our company as it allows us to better serve our customers worldwide.  We look forward to working with our partners to advance their clinical pipelines with the ultimate goal of helping patients worldwide."

About WuXi Biologics 

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics from concept to commercialization for the benefit of patients worldwide.

With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2022, WuXi Biologics is supporting 534 integrated client projects, including 14 in commercial manufacturing.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

Media 
PR@wuxibiologics.com 

Business
info@wuxibiologics.com

View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-announces-gmp-release-of-its-first-north-american-biomanufacturing-facility-in-cranbury-new-jersey-301615402.html

SOURCE WuXi Biologics

FAQ

What is the significance of WuXi Biologics' new facility in Cranbury, NJ?

The new facility represents WuXi's first GMP biomanufacturing site in North America, enhancing its capacity to serve U.S. clients and strengthen its market position.

What capacity does the GMP facility in Cranbury, NJ have?

The facility has an initial capacity of 4,000L, which is expected to grow to 6,000L.

How many employees will the Cranbury facility employ?

The facility currently employs over 150 people, with an anticipated increase to over 250 when fully operational.

What technology does WuXi Biologics' Cranbury facility utilize?

The Cranbury facility utilizes single-use technology in its manufacturing operations.